Peter F. Lenehan

Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone

Eric J. Small, Mark Meyer, M. Ernest Marshall et al. · Journal of Clinical Oncology · 2000 · 188 citations

Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer

Pasi A. Jänne, Joachim von Pawel, Roger B. Cohen et al. · Journal of Clinical Oncology · 2007 · 118 citations · Full text

Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer

Susana M. Campos, Oday Hamid, Michael V. Seiden et al. · Journal of Clinical Oncology · 2005 · 108 citations · Full text

Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer

John Nemunaitis, Irene Eiseman, Casey Cunningham et al. · Clinical Cancer Research · 2005 · 86 citations · Full text

Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival

Eric J. Small, Alex McMillan, Mark Meyer et al. · Journal of Clinical Oncology · 2001 · 84 citations